Imperial College London
Alternate

DrVikKhullar

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Practice (Urogynaecology)
 
 
 
//

Contact

 

+44 (0)20 3312 1959vik.khullar

 
 
//

Location

 

Urogynaecology DeptCambridge WingSt Mary's Campus

//

Summary

 

Publications

Publication Type
Year
to

511 results found

Bhide AA, Cartwright R, Khullar V, Digesu GAet al., 2013, Biomarkers in overactive bladder (vol 24, pg 1065, 2013), INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1775-1777, ISSN: 0937-3462

Journal article

Oelke M, Khullar V, Wijkstra H, 2013, Review on ultrasound measurement of bladder or detrusor wall thickness in women: techniques, diagnostic utility, and use in clinical trials, WORLD JOURNAL OF UROLOGY, Vol: 31, Pages: 1093-1104, ISSN: 0724-4983

Journal article

Khullar V, Cambronero J, Angulo JC, Wooning M, Blauwet MB, Dorrepaal C, Martin NEet al., 2013, Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial, BMC Urology, Vol: 13, Pages: 1-9, ISSN: 1471-2490

BackgroundAntimuscarinic agents are currently the predominant treatment option for the clinical management of the symptoms of overactive bladder (OAB). However, low rates of persistence with these agents highlight the need for novel, effective and better-tolerated oral pharmacological agents. Mirabegron is a β3-adrenoceptor agonist developed for the treatment of OAB, with a mechanism of action distinct from that of antimuscarinics. In a randomized, double-blind, placebo- and active-controlled Phase 3 trial conducted in Europe and Australia (NCT00689104), mirabegron 50 mg and 100 mg resulted in statistically significant reductions from baseline to final visit, compared with placebo, in the co-primary end points – mean number of incontinence episodes/24 h and mean number of micturitions/24 h. We conducted a post hoc, subgroup analysis of this study in order to evaluate the efficacy of mirabegron in treatment-naïve patients and patients who had discontinued prior antimuscarinic therapy because of insufficient efficacy or poor tolerability.MethodsPatients were randomized to placebo, mirabegron 50 or 100 mg, or tolterodine extended release (ER) 4 mg orally, once-daily, for 12 weeks. For the post hoc analysis, the primary patient population was divided into the following subgroups: (1) patients who had not received any prior antimuscarinic OAB medication (treatment-naïve) and (2) patients who had received prior antimuscarinic OAB medication. The latter subgroup was further subdivided into patients who discontinued due to: (3) insufficient efficacy or (4) poor tolerability. Analysis of the co-primary efficacy endpoints by subgroup was performed using analysis of covariance with treatment group, subgroup, sex, geographical region, and subgroup-by-treatment interaction as fixed factors; and baseline value as a covariate.ResultsMirabegron, 50 mg and 100 mg once-daily, demonstrated similar improvements in the frequency of incontinence episodes and micturit

Journal article

Bhide AA, Puccini F, Khullar V, Elneil S, Digesu GAet al., 2013, Botulinum neurotoxin type A injection of the pelvic floor muscle in pain due to spasticity: a review of the current literature, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1429-1434, ISSN: 0937-3462

Journal article

Khullar V, Marschall-Kehrel D, Espuna-Pons M, Kelleher CJ, Tully SE, Piault EC, Brubaker L, Fianu-Jonasson A, Weinstein D, Bergqvist A, Kvasz Met al., 2013, European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1529-1536, ISSN: 0937-3462

Journal article

Vijaya G, Cartwright R, Derpapas A, Gallo P, Fernando R, Khullar Vet al., 2013, Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1523-1528, ISSN: 0937-3462

Journal article

Sorrentino F, Tolton L, Cartwright R, Pass D, Franklin L, Greco P, Khullar V, Digesu Aet al., 2013, IS "ASYMPTOMATIC" BACTERIURIA ALWAYS ASYMPTOMATIC? ASSOCIATIONS BETWEEN INDIVIDUAL FEMALE LOWER URINARY TRACT SYMPTOMS AND SUBCLINICAL BACTERIAL INFECTION IN RANDOM URINE SAMPLES, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 699-700, ISSN: 0733-2467

Conference paper

Bray R, Cartwright R, Tikkinen K, Singh AU, Gopalan V, Digesu A, Fernando R, Khullar V, Jarvelin Met al., 2013, POST-PARTUM INCONTINENCE, BMI AND LOWER URINARY TRACT SYMPTOMS AT MIDILFE: 12-YEAR FOLLOW-UP OF A POPULATION-BASED PROSPECTIVE COHORT, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 591-592, ISSN: 0733-2467

Conference paper

Khullar V, Nitti V, Dmochowski R, Sand P, Chapple C, Sievert K, MacDiarmid S, Radziszewski P, Nardo C, Zhou J, Haag-Molkenteller C, Herschorn Set al., 2013, ONABOTULINUMTOXINA SIGNIFICANTLY DECREASES URINARY INCONTINENCE AND PROVIDES TREATMENT BENEFIT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER: A POOLED ANALYSIS OF TWO PHASE III, PLACEBO-CONTROLLED PIVOTAL TRIALS, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 765-765, ISSN: 0733-2467

Conference paper

Chapple C, Sievert K-D, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller Cet al., 2013, OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial, EUROPEAN UROLOGY, Vol: 64, Pages: 249-256, ISSN: 0302-2838

Journal article

Dutta S, Cartwright R, Tikkinen K, Bray R, Khullar V, Spector T, Jarvelin Met al., 2013, PREVALENCE AND RISK FACTORS FOR SYMPTOMATIC PELVIC ORGAN PROLAPSE USING THE ICIQ-VAGINAL SYMPTOMS QUESTIONNAIRE: RESULTS FROM THE TWINSUK ADULT TWIN REGISTRY, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 861-862, ISSN: 0733-2467

Conference paper

Vijaya G, Dutta S, Singh AU, Bray R, Digesu A, Fernando R, Khullar Vet al., 2013, BACTERIA IN THE BLADDER WALL OF WOMEN WITH LOWER URINARY TRACT SYMPTOMS: AN INTERESTING FINDING, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 695-696, ISSN: 0733-2467

Conference paper

Tubaro A, Khullar V, Oelke M, Wijkstra H, Tretter R, Stow B, Huang M, Compion G, Robinson Det al., 2013, INTRA- AND INTER-READER VARIABILITY OF TRANSVAGINAL ULTRASOUND BLADDER WALL THICKNESS MEASUREMENTS: RESULTS FROM THE SHRINK STUDY, 43rd Annual Meeting of the International-Continence-Society (ICS), Publisher: WILEY-BLACKWELL, Pages: 711-712, ISSN: 0733-2467

Conference paper

Angulo JC, Khullar V, Nitti VW, Siddiqui Eet al., 2013, Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder, ACTAS UROLOGICAS ESPANOLAS, Vol: 37, Pages: 640-651, ISSN: 0210-4806

Journal article

Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NEet al., 2013, Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies, International Journal of Clinical Practice, Vol: 67, Pages: 619-632, ISSN: 1368-5031

IntroductionTo examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results.MethodsThis prespecified pooled analysis of three randomised, double‐blind, placebo‐controlled, 12‐week studies, evaluated efficacy and safety of once‐daily mirabegron 25 mg (safety analysis), 50 or 100 mg (efficacy and safety analyses) and tolterodine ER 4 mg (safety analysis) for the treatment of symptoms of overactive bladder (OAB). Co‐primary efficacy measures were change from baseline to Final Visit in the mean number of incontinence episodes/24 h and mean number of micturitions/24 h. Key secondary efficacy end‐points included mean number of urgency episodes/24 h and mean volume voided/micturitions, while other end‐points included patient‐reported outcomes according to the Treatment Satisfaction‐Visual Analogue Scale (TS‐VAS) and responder analyses [dry rate (posttreatment), ≥ 50% reduction in incontinence episodes/24 h, ≤ 8 micturitions/24 h (post hoc analysis)]. The safety analysis included adverse event (AE) reporting, laboratory assessments, ECG, postvoid residual volume and vital signs (blood pressure, pulse rate).ResultsMirabegron (50 and 100 mg once daily) demonstrated statistically significant improvements compared with placebo for the co‐primary end‐points, key secondary efficacy variables, TS‐VAS and responder analyses (all comparisons p < 0.05). Mirabegron is well tolerated and demonstrates a good safety profile. The most common AEs (≥ 3%) included hypertension, nasopharyngitis and urinary tract infection (UTI); the incidence of hypertensive events and UTIs decreased with increasing dose. For mirabegron, the incidence of the bothersome antimuscarinic AE, dry mouth, was at placebo level and of a lesser magnitude than tolterodine.ConclusionThe efficacy and safety of mirabegron are demonstrated in this

Journal article

Digesu GA, Sadenghi P, Sharma S, Puccini F, Tubaro A, Fernando R, Khullar Vet al., 2013, The importance of cystoscopy and bladder biopsy in women with refractory overactive bladder: the urogynaecologist's point of view?, EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, Vol: 169, Pages: 408-411, ISSN: 0301-2115

Journal article

Bhide AA, Cartwright R, Khullar V, Digesu GAet al., 2013, Biomarkers in overactive bladder, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: 1065-1072, ISSN: 0937-3462

Journal article

Siddiqui E, Nitti V, Herschorn S, Khullar V, Cambronero J, Angulo J, Blauwet MB, Dorrepaal C, Van Kerrebroek P, Martin NEet al., 2013, Efficacy of mirabegron in patients with overactive bladder (OAB): Pre-specified analysis of three randomized, double-blind, placebo-controlled, Phase III studies, Annual Scientific Meeting of the British-Association-of-Urological-Surgeons (BAUS), Publisher: WILEY-BLACKWELL, Pages: 56-56, ISSN: 1464-4096

Conference paper

Chapple CR, Khullar V, Nitti VW, Herschorn S, Kaper M, Dorrepaal C, Martin N, Siddiqui Eet al., 2013, EFFICACY OF MIRABEGRON IN OVERACTIVE BLADDER PATIENTS STRATIFIED BY SEVERITY OF BASELINE INCONTINENCE: A POST-HOC ANALYSIS OF POOLED DATA FROM 3 RANDOMISED PHASE 3 TRIALS, Publisher: SPRINGER LONDON LTD, Pages: S12-S13, ISSN: 0937-3462

Conference paper

Bray R, Cartwright R, Tikkinen K, Singh A, Khullar V, Lawlor D, Jarvelin Met al., 2013, THE IMPACT OF POST-PARTUM INCONTINENCE ON LOWER URINARY TRACT SYMPTOMS: 12-YEAR FOLLOW-UP OF A POPULATION-BASED PROSPECTIVE COHORT, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S80-S81, ISSN: 0937-3462

Journal article

Digesu A, Swift S, Ortiz OC, Manonai J, Fernando R, Khullar V, Salvatore Set al., 2013, THE FIGO ASSESSMENT SCORING SYSTEM (FASS) A NEW HOLISTIC CLASSIFICATION TOOL TO ASSESS WOMEN WITH PELVIC FLOOR DYSFUNCTION, Publisher: SPRINGER LONDON LTD, Pages: S15-S16, ISSN: 0937-3462

Conference paper

Khullar V, Sand P, Parsons M, Zhou J, Globe D, Nardo Cet al., 2013, ONABOTULINUMTOXINA SIGNIFICANTLY REDUCES URINARY INCONTINENCE AND IMPROVES QUALITY OF LIFE IN FEMALE PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S13-S14, ISSN: 0937-3462

Journal article

Cartwright R, Kirby A, Thiagamoorthy G, Tikkinen KA, Pesonen J, Mangera A, Walley AJ, Bennett PR, Palmer T, Jaervelin M, Chapple CR, Khullar Vet al., 2013, A SYSTEMATIC REVIEW AND META-ANALYSIS OF CANDIDATE GENE ASSOCIATION STUDIES OF LOWER URINARY TRACT SYMPTOMS AND PELVIC ORGAN PROLAPSE IN WOMEN., INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S2-S3, ISSN: 0937-3462

Journal article

Sand P, Khullar V, Cardozo L, Koelbl H, Salvatore S, Blauwet M, Martin Net al., 2013, EFFICACY OF MIRABEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN FEMALE PATIENTS: PROSPECTIVE POOLED ANALYSIS OF 3 RANDOMISED PHASE 3 TRIALS, Publisher: SPRINGER LONDON LTD, Pages: S10-S12, ISSN: 0937-3462

Conference paper

Vijaya G, Puccini F, Dutta S, Singh A, Bray R, Digesu A, Fernando R, Khullar Vet al., 2013, IS THERE BACTERIAL INFECTION IN THE BLADDER WALL OF PATIENTS WITH REFRACTORY OVERACTIVE BLADDER?, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S79-S79, ISSN: 0937-3462

Journal article

Derpapas A, Vijaya G, Digesu AG, Fernando R, Khullar Vet al., 2013, CLINICAL AND ULTRASONOGRAPHIC ASSESSMENT OF TWO DIFFERENT SURGICAL TECHNIQUES FOR POSTERIOR VAGINAL WALL REPAIR: A RANDOMISED CONTROL TRIAL., INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S127-S127, ISSN: 0937-3462

Journal article

Singh AU, Cartwright R, Bray R, Gonzalez J, Khullar V, Jarvelin M, Lawlor DAet al., 2013, THE PREVALENCE OF LOWER URINARY TRACT SYMPTOMS IN WOMEN AGED 18-20: RESULTS FROM A POPULATION-BASED BIRTH COHORT, INTERNATIONAL UROGYNECOLOGY JOURNAL, Vol: 24, Pages: S82-S82, ISSN: 0937-3462

Journal article

Kirby A, Cartwright R, Tikkinen K, Palmer T, Thiagamoorthy G, Rajan P, Pesonen J, Walley A, Mangera A, Grigoriadis G, Ambrose C, Jarvelin M-R, Bennett P, Chapple C, Khullar Vet al., 2013, CANDIDATE GENE ASSOCIATION STUDIES OF URINARY SYMPTOMS AND PELVIC ORGAN PROLAPSE IN WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS, Annual Meeting of the American-Urological-Association (AUA), Publisher: ELSEVIER SCIENCE INC, Pages: E47-E47, ISSN: 0022-5347

Conference paper

Derpapas A, Digesu AG, Hamady M, Gallo P, Dell'Utri C, Vijaya G, Khullar Vet al., 2013, Prevalence of pubovisceral muscle avulsion in a general gynecology cohort: A computed tomography (CT) study, NEUROUROLOGY AND URODYNAMICS, Vol: 32, Pages: 359-362, ISSN: 0733-2467

Journal article

Tikkinen K, Cartwright R, Kirby A, Mangera A, Thiagamoorthy G, Rajan P, Pesonen J, Palmer T, Ambrose C, Khullar V, Walley A, Jarvelin M-R, Bennett P, Chapple Cet al., 2013, CANDIDATE GENE ASSOCIATION STUDIES OF LOWER URINARY TRACT SYMPTOMS IN MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS, Annual Meeting of the American-Urological-Association (AUA), Publisher: ELSEVIER SCIENCE INC, Pages: E712-E712, ISSN: 0022-5347

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: limit=30&id=00304026&person=true&page=7&respub-action=search.html